Prevention

Kenneth P. Klinker, PharmD, and Jason M. Pogue, PharmD, share some strategies to address beta-lactam dosing issues that they employ at their institutions.

Edward J. Septimus, MD, explains how smaller hospitals can overcome the challenges that come with having fewer resources to implement a robust antibiotic stewardship program.

The drug met its primary endpoint of noninferiority to vancomycin at both 48 to 72 hours after drug initiation and test of cure.

Jason M. Pogue, PharmD, discusses the challenges clinicians face when dosing beta-lactams based on the current guidelines.

In case you missed them, we’ve compiled a list of the latest recalls posted this week.

Brain damage caused by HIV can begin soon after infection, according to new research, but initiating antiretroviral therapy drugs can halt the damage.

In case you missed them, we've compiled the top 5 articles from this past week.

Bruce A. Mueller, PharmD, shares how clinicians in the inpatient setting can quantify acute kidney injury in adults on antibiotics.

A new study shows the benefits of widespread antibiotic distribution, but what about concerns about encouraging antibiotic resistance?

A study shows that pharmacist-driven education and encouragement of antibiotic self-stewardship can decrease the duration of therapy for broad-spectrum antibiotics.

An economic evaluation finds that a bundled approach of stronger hand hygiene and improved environmental cleaning proved to be the best combination for reducing C. diff.

A new literature review offers a summary of the latest research into uncomplicated bacteremia.

A phase 2 trial of an experimental universal flu vaccine is moving forward with sponsorship from The National Institute of Allergy and Infectious Diseases.

Novavax announces that enrollment in phase 3 Prepare trial has reached approximately 4,600 participants, of whom, at least 3,000 have received the RSV F vaccine.

If clinical development progresses, the PaxVax vaccine could potentially become the first vaccine approved by the FDA for the prevention of chikungunya.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A recent study has found that a single-dose of Merck's Ebola vaccine delivers antibodies that can last for 1 to 2 years.

Data from the IGNITE4 phase 3 trial supports the use of eravacycline for the treatment of complicated intra-abdominal infections (cIAI), including infections caused by pathogens resistant to other antibiotics.

New software unveiled last month suggests hospitals could make patient-specific predictions of antibiotic susceptibility.

The rise in antibiotic resistance has led experts to focus on how to appropriately manage and regulate shared-use antibiotics in humans and animals.

Julia E. Szymczak, PhD, shares the results of her study which revealed that fear drives some clinicians to prescribe inappropriately.

This emotional drive carried throughout the continuum of the prescribing pathway, from initial prescription to stopping or de-escalating antibiotics.

New CDC report warns of the growing burden of vector-borne diseases in the United States.

Investigational beta-lacatamase inhibitor IMI/REL demonstrates a favorable overall response against certain imipenem-non-susceptible bacterial infections.

Dr. Gonzalo Bearman delves into the use of contact precautions for endemic pathogens such as MRSA and VRE and assesses the effectiveness of this approach.